The Acute and Long-term Impact of Support and Music in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522961-31-00

Enrollment

120

Registered

2026-03-24

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

The primary endpoint of this study will be the change in depressive symptoms measured by the MADRS from baseline to the 6-week follow-up, assessed by a blinded rater.

Interventions

DRUGPEX010 Psilocybin Capsules ( 25mg psilocybin)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint of this study will be the change in depressive symptoms measured by the MADRS from baseline to the 6-week follow-up, assessed by a blinded rater.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 25, 2026